Compare Fox Corp Class A (FOXA) vs Pfizer Inc (PFE) Price & Performance

Fox Corporation (FOXA) trades at $56.69, up 3.32% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 results, beating EPS estimates, and completed a transformative $22 billion acquisition of Roku in June 2026. Fundamentals show revenue growth to $16.3B in 2025 with a 13.88% net margin, while valuation metrics appear reasonable with a P/E of 14.73 and EV/EBITDA of 8.42.

The outlook balances strategic positioning through the Roku acquisition against integration risks and leverage concerns. Analyst consensus is evenly split between Buy and Hold with a $67.80 price target suggesting 19.6% upside, but technical indicators remain bearish and projected 2026 cash flow turns negative. Key risks include streaming competition, advertising cyclicality, and debt servicing from the Roku deal.

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.